Handelsbanken Fonder AB Purchases 9,200 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Handelsbanken Fonder AB increased its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 16.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 64,366 shares of the biotechnology company’s stock after buying an additional 9,200 shares during the period. Handelsbanken Fonder AB’s holdings in Exelixis were worth $1,544,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of EXEL. Contravisory Investment Management Inc. bought a new stake in shares of Exelixis during the 4th quarter worth $26,000. Denali Advisors LLC raised its stake in Exelixis by 7,995.2% during the 3rd quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,679 shares during the last quarter. Fifth Third Bancorp raised its stake in Exelixis by 44.2% during the 3rd quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 604 shares during the last quarter. Signaturefd LLC raised its stake in Exelixis by 17.1% during the 3rd quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 668 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in Exelixis during the 3rd quarter valued at $100,000. 85.27% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on EXEL. William Blair reiterated an “outperform” rating on shares of Exelixis in a research note on Friday, January 26th. JMP Securities reiterated a “market outperform” rating and set a $27.00 target price on shares of Exelixis in a research note on Wednesday, April 10th. Stifel Nicolaus upped their target price on shares of Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a research note on Friday, February 2nd. TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, March 18th. Finally, Barclays cut shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 price objective for the company. in a research note on Thursday, April 11th. Six investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Exelixis presently has an average rating of “Moderate Buy” and an average price target of $26.29.

Exelixis Stock Up 0.7 %

Shares of Exelixis stock opened at $23.70 on Friday. The stock has a market capitalization of $6.99 billion, a P/E ratio of 37.03, a price-to-earnings-growth ratio of 0.61 and a beta of 0.54. The company has a 50-day simple moving average of $22.80 and a 200 day simple moving average of $22.19. Exelixis, Inc. has a 12-month low of $18.08 and a 12-month high of $24.34.

Exelixis (NASDAQ:EXEL) last announced its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.02. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. The business had revenue of $479.65 million during the quarter, compared to analysts’ expectations of $481.23 million. On average, equities analysts anticipate that Exelixis, Inc. will post 1.24 earnings per share for the current year.

Insiders Place Their Bets

In other Exelixis news, Director Alan M. Garber sold 19,205 shares of the stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $24.01, for a total transaction of $461,112.05. Following the sale, the director now owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other Exelixis news, EVP Patrick J. Haley sold 47,020 shares of the stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $21.45, for a total transaction of $1,008,579.00. Following the sale, the executive vice president now owns 384,866 shares of the company’s stock, valued at approximately $8,255,375.70. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Alan M. Garber sold 19,205 shares of the firm’s stock in a transaction dated Thursday, March 21st. The shares were sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the transaction, the director now directly owns 35,703 shares in the company, valued at approximately $857,229.03. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.